Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Baxter
Colorcon
Johnson and Johnson

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LY3314814


Email this page to a colleague

« Back to Dashboard

Clinical Trials for LY3314814

Trial ID Title Status Sponsor Phase Summary
NCT02245737 ↗ An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Terminated AstraZeneca Phase 2/Phase 3 The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2 lanabecestat treatment groups compared with placebo.
NCT02245737 ↗ An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Terminated Eli Lilly and Company Phase 2/Phase 3 The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2 lanabecestat treatment groups compared with placebo.
NCT02406261 ↗ A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants Completed AstraZeneca Phase 1 The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study
NCT02406261 ↗ A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants Completed Eli Lilly and Company Phase 1 The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study
NCT02540668 ↗ A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants Completed AstraZeneca Phase 1 The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for LY3314814

Condition Name

Condition Name for
Intervention Trials
Healthy 7
Alzheimer's Disease 2
Hepatic Impairment 1
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Alzheimer Disease 3
Dementia 2
Renal Insufficiency 1
Liver Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LY3314814

Trials by Country

Trials by Country for
Location Trials
United States 85
Japan 45
United Kingdom 21
Spain 19
Germany 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Florida 7
California 5
Texas 4
Tennessee 4
Indiana 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LY3314814

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 1 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 6
Terminated 3
Withdrawn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LY3314814

Sponsor Name

Sponsor Name for
Sponsor Trials
AstraZeneca 21
Eli Lilly and Company 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Baxter
Merck
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.